 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase or decrease the risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"alendronate"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ALENDRONATE: dosage_and_administration: [0m[1;31m3[0m[31m Important Administration Instructions Instruct patients to do the following to assure adequate drug absorption and to decrease the risk of esophageal[0m
[31madverse reactions: i. Take BINOSTO upon arising for the day and at least [0m[1;31m30[0m[31m minutes before the first food, beverage, or medication of the day. Patients should not swallow the undissolved effervescent [0m
[31mtablet, should not chew the effervescent tablet or allow the effervescent tablet to dissolve in their mouths because of the risk for oropharyngeal irritation [0m[31m. Dissolve the effervescent tablet in [0m[1;31m4[0m[31m [0m
[31mounces room temperature plain water only [0m[1;31m([0m[31mnot mineral water or flavored water[0m[1;31m)[0m[31m. ii. Wait at least [0m[1;31m5[0m[31m minutes after the effervescence stops and then stir the buffered solution for approximately [0m[1;31m10[0m[31m [0m
[31mseconds and ingest. iii. Avoid lying down for at least [0m[1;31m30[0m[31m minutes after taking BINOSTO and until after their first food of the day. iv. ALENDRONATE: dosage_and_administration: Do not take BINOSTO at [0m
[31mbedtime or before arising for the day. Failure to follow these instructions may increase the risk of esophageal adverse reactions [0m[31m . [0m[1;31m2.4[0m[31m Recommendations for Calcium and Vitamin D Supplementation [0m
[31mInstruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate [0m[31m . Patients at increased risk for vitamin D insufficiency [0m[1;31m([0m[31me.g., over the age of [0m[1;31m70[0m[31m years, nursing [0m
[31mhome-bound, or chronically ill[0m[1;31m)[0m[31m may need vitamin D supplementation. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplementation and measurement of [0m
[1;31m25[0m[31m-hydroxyvitamin D should be considered. [0m[1;31m2.5[0m[31m Administration Instructions for Missed Doses If the once-weekly dose is missed, instruct patients to take one dose on the morning after they remember. [0m
[31mALENDRONATE: dosage_and_administration: They should not take [0m[1;31m2[0m[31m doses on the same day but should return to taking one dose once a week, as originally scheduled on their chosen day.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new or [0m
[31mworsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE: warnings_and_cautions: [0m[1;31m1[0m[31m Upper Gastrointestinal [0m
[31mAdverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential [0m
[31mfor worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, dysphagia, other [0m
[31mesophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed [0m
[31mby esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe and required [0m
[31mhospitalization. ALENDRONATE: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to [0m
[31mdiscontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences appears to be [0m
[31mgreater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after developing symptoms[0m
[31msuggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot comply with dosing [0m
[31minstructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision. ALENDRONATE: warnings_and_cautions: There have been post-marketing reports of gastric and [0m
[31mduodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials [0m[31m . [0m[1;31m5.2[0m[31m Mineral Metabolism Hypocalcemia must be [0m
[31mcorrected before initiating therapy with BINOSTO [0m[31m. Other disorders affecting mineral metabolism [0m[1;31m([0m[31msuch as vitamin D deficiency[0m[1;31m)[0m[31m should also be effectively treated. In patients with these conditions, [0m
[31mserum calcium and symptoms of hypocalcemia should be monitored during therapy with BINOSTO. Presumably due to the effects of BINOSTO on increasing bone mineral, small, asymptomatic decreases in serum [0m
[31mcalcium and phosphate may occur. Patients should receive adequate calcium and vitamin D intake. [0m[1;31m5[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: clinical_pharmacology: While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts[0m
[31mon newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover [0m[1;31m([0m[31mi.e., the number of sites at which bone is remodeled[0m[1;31m)[0m[31m. In addition, [0m
[31mbone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass. [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and[0m
[31mspecifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately [0m
[31mreduced because bone resorption and formation are coupled during bone turnover. ALENDRONATE: clinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass [0m
[31mthat leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of low bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or [0m
[31mkyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females but is most common among women following the menopause, when bone turnover increases and the rate of [0m
[31mbone resorption exceeds that of bone formation. These changes result in progressive bone loss and lead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the [0m
[31mspine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to age [0m[1;31m90[0m[31m, the risk of hip fracture in white women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. ALENDRONATE: [0m
[31mclinical_pharmacology: It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or more osteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes.[0m
[31mHip fractures, in particular, are associated with substantial morbidity, disability, and mortality. Daily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women [0m
[31mproduced biochemical changes indicative of dose-dependent inhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as [0m
[31mdeoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. These biochemical changes tended to return toward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy [0m
[31mwith alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. ALENDRONATE: clinical_pharmacology: Long-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m [0m
[31mreduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to [0m
[31mthose seen in healthy premenopausal women. Similar decreases were seen in patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone [0m
[31mresorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium. [0m
[31mALENDRONATE: clinical_pharmacology: In osteoporosis treatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by [0m
[31mapproximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In osteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased [0m
[31mosteocalcin and total serum alkaline phosphatase by approximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively. Similar reductions in the rate of bone turnover were observed in postmenopausal women during one-year [0m
[31mstudies with once weekly alendronate sodium [0m[1;31m70[0m[31m mg for the treatment of osteoporosis and once weekly alendronate sodium [0m[1;31m35[0m[31m mg for the prevention of osteoporosis. These data indicate that the rate of [0m
[31mbone turnover reached a new steady state, despite the progressive increase in the total amount of alendronate deposited within bone. ALENDRONATE: clinical_pharmacology: As a result of inhibition of [0m
[31mbone resorption, asymptomatic reductions in serum calcium and phosphate concentrations were also observed following treatment with alendronate sodium. In the long-term studies, reductions from [0m
[31mbaseline in serum calcium [0m[1;31m([0m[31mapproximately [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m and phosphate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m to [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m were evident the first month after the initiation of alendronate sodium [0m[1;31m10[0m[31m mg. No further decreases in serum calcium [0m
[31mwere observed for the five-year duration of treatment; however, serum phosphate returned toward prestudy levels during years three through five. Similar reductions were observed with alendronate [0m
[31msodium [0m[1;31m5[0m[31m mg/day. In one-year studies with once weekly alendronate sodium [0m[1;31m35[0m[31m and [0m[1;31m70[0m[31m mg, similar reductions were observed at [0m[1;31m6[0m[31m and [0m[1;31m12[0m[31m months. The reduction in serum phosphate may reflect not only the [0m
[31mpositive bone mineral balance due to alendronate sodium but also a decrease in renal phosphate reabsorption. ALENDRONATE: clinical_pharmacology: Osteoporosis in Men Treatment of men with osteoporosis [0m
[31mwith alendronate sodium [0m[1;31m10[0m[31m mg/day for two years reduced urinary excretion of cross-linked N-telopeptides of type I collagen by approximately [0m[1;31m60[0m[31m% and bone-specific alkaline phosphatase by approximately[0m
[1;31m40[0m[31m%. Similar reductions were observed in a one-year study in men with osteoporosis receiving once weekly alendronate sodium [0m[1;31m70[0m[31m mg. [0m[1;31m12.3[0m[31m Pharmacokinetics Absorption Relative to an intravenous [0m[1;31m([0m[31mIV[0m[1;31m)[0m[31m [0m
[31mreference dose, the mean oral bioavailability of alendronate in women was [0m[1;31m0.64[0m[31m% for doses ranging from [0m[1;31m5[0m[31m to [0m[1;31m70[0m[31m mg when administered after an overnight fast and two hours before a standardized [0m
[31mbreakfast. Oral bioavailability of the [0m[1;31m10[0m[31m mg tablet in men [0m[1;31m([0m[1;31m0.59[0m[31m%[0m[1;31m)[0m[31m was similar to that in women when administered after an overnight fast and [0m[1;31m2[0m[31m hours before breakfast. ALENDRONATE: [0m
[31mclinical_pharmacology: BINOSTO [0m[1;31m70[0m[31m mg effervescent tablet and alendronate sodium [0m[1;31m70[0m[31m mg tablet are bioequivalent. A study evaluating the effect of food on the bioavailability of BINOSTO was performed in[0m
[1;31m119[0m[31m healthy women. Bioavailability was decreased [0m[1;31m([0m[31mby approximately [0m[1;31m50[0m[31m%[0m[1;31m)[0m[31m when [0m[1;31m70[0m[31m mg alendronate sodium was administered [0m[1;31m15[0m[31m minutes before a standardized breakfast, when compared to dosing [0m[1;31m4[0m[31m hours [0m
[31mbefore eating. In studies of treatment and prevention of osteoporosis, alendronate was effective when administered at least [0m[1;31m30[0m[31m minutes before breakfast. Bioavailability was negligible whether [0m
[31malendronate sodium was administered with or up to [0m[1;31m2[0m[31m hours after a standardized breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately[0m
[1;31m60[0m[31m%.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: pharmacodynamics: Similar decreases were seen in patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption[0m
[31mindicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium. In osteoporosis [0m
[31mtreatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by[0m
[31mapproximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In osteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by [0m
[31mapproximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively. ALENDRONATE: pharmacodynamics: Similar reductions in the rate of bone turnover were observed in postmenopausal women during one-year studies with once weekly [0m
[31malendronate sodium [0m[1;31m70[0m[31m mg for the treatment of osteoporosis and once weekly alendronate sodium [0m[1;31m35[0m[31m mg for the prevention of osteoporosis. These data indicate that the rate of bone turnover reached a new[0m
[31msteady state, despite the progressive increase in the total amount of alendronate deposited within bone. As a result of inhibition of bone resorption, asymptomatic reductions in serum calcium and [0m
[31mphosphate concentrations were also observed following treatment with alendronate sodium. In the long-term studies, reductions from baseline in serum calcium [0m[1;31m([0m[31mapproximately [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m and phosphate [0m
[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m to [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m were evident the first month after the initiation of alendronate sodium [0m[1;31m10[0m[31m mg. No further decreases in serum calcium were observed for the five-year duration of treatment; [0m
[31mhowever, serum phosphate returned toward prestudy levels during years three through five. ALENDRONATE: pharmacodynamics: Similar reductions were observed with alendronate sodium [0m[1;31m5[0m[31m mg/day. In one-year [0m
[31mstudies with once weekly alendronate sodium [0m[1;31m35[0m[31m and [0m[1;31m70[0m[31m mg, similar reductions were observed at [0m[1;31m6[0m[31m and [0m[1;31m12[0m[31m months. The reduction in serum phosphate may reflect not only the positive bone mineral balance [0m
[31mdue to alendronate sodium but also a decrease in renal phosphate reabsorption. Osteoporosis in Men Treatment of men with osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day for two years reduced urinary [0m
[31mexcretion of cross-linked N-telopeptides of type I collagen by approximately [0m[1;31m60[0m[31m% and bone-specific alkaline phosphatase by approximately [0m[1;31m40[0m[31m%. Similar reductions were observed in a one-year study in [0m
[31mmen with osteoporosis receiving once weekly alendronate sodium [0m[1;31m70[0m[31m mg.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Alendronate, when not administered according to the proper guidelines, can increase the risk of hospitalization due to severe esophageal adverse reactions, which in some cases have been severe[0m
[32mand required hospitalization. It is important for patients to follow dosing instructions to decrease the risk of these adverse reactions.[0m

[32mSOURCE: ALENDRONATE label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32mesophageal erosions, occasionally with bleeding and rarely followed by[0m[32m...[0m[32mrequired hospitalization.[0m
*[1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Alendronate, when not administered according to the proper [0m
[34mguidelines, can increase the risk of hospitalization due to severe esophageal adverse reactions, which in some cases have been severe and required hospitalization. It is important for patients to [0m
[34mfollow dosing instructions to decrease the risk of these adverse reactions.[0m

[34mSOURCE: ALENDRONATE label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34mesophageal erosions, occasionally with bleeding and rarely followed by[0m[34m...[0m[34mrequired hospitalization.[0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if ALENDRONATE increases or decreases the risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that Alendronate can increase the risk of hospitalization due to severe esophageal adverse reactions when not administered according to proper guidelines. It is important [0m
[32mfor patients to follow dosing instructions to decrease the risk of these adverse reactions."[0m[32m,[0m
[32m      [0m[32m"The source of this information is the ALENDRONATE label."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Alendronate can increase the risk of hospitalization due to severe esophageal adverse reactions, particularly when not used according to the proper guidelines. It is important to follow[0m
[32mdosing instructions to minimize this risk."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ALENDRONATE increase or decrease the risk of hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if ALENDRONATE increases or decreases the risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that Alendronate can increase the risk of hospitalization due to severe esophageal adverse reactions when not administered according to proper guidelines. It is important [0m
[34mfor patients to follow dosing instructions to decrease the risk of these adverse reactions."[0m[34m,[0m
[34m      [0m[34m"The source of this information is the ALENDRONATE label."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Alendronate can increase the risk of hospitalization due to severe esophageal adverse reactions, particularly when not used according to the proper guidelines. It is important to follow[0m
[34mdosing instructions to minimize this risk."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ALENDRONATE increase or decrease the risk of hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if ALENDRONATE increases or decreases the risk of hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that Alendronate can increase the risk of hospitalization due to severe esophageal adverse reactions when not administered according to proper guidelines. It is important for [0m
[31mpatients to follow dosing instructions to decrease the risk of these adverse reactions.[0m
[1;31m3[0m[31m. The source of this information is the ALENDRONATE label.[0m
[31m        -----[0m
[31m        Final answer: Alendronate can increase the risk of hospitalization due to severe esophageal adverse reactions, particularly when not used according to the proper guidelines. It is important to[0m
[31mfollow dosing instructions to minimize this risk.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mAlendronate can increase the risk of hospitalization due to severe esophageal adverse reactions, particularly when not used according to the proper guidelines. It is important to follow dosing [0m
[32minstructions to minimize this risk.[0m
